The antiphospholipid syndrome in patients with systemic lupus erythematosus

Gomez-Puerta, 2014, Diagnosis and classification of the antiphospholipid syndrome, J. Autoimmun., 48–49, 20, 10.1016/j.jaut.2014.01.006 Hughes, 1983, Thrombosis, abortion, cerebral disease, and the lupus anticoagulant, Br. Med. J. Clin. Res. Ed., 287, 1088, 10.1136/bmj.287.6399.1088 Cervera, 2002, Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients, Arthritis Rheum., 46, 1019, 10.1002/art.10187 Biggioggero, 2010, The geoepidemiology of the antiphospholipid antibody syndrome, Autoimmun. Rev., 9, A299, 10.1016/j.autrev.2009.11.013 Cervera, 2008, Lessons from the “Euro-Phospholipid” project, Autoimmun. Rev., 7, 174, 10.1016/j.autrev.2007.11.011 Appenzeller, 2011, HELLP syndrome and its relationship with antiphospholipid syndrome and antiphospholipid antibodies, Semin. Arthritis Rheum., 41, 517, 10.1016/j.semarthrit.2011.05.007 Tincani, 2009, Neonatal effects of maternal antiphospholipid syndrome, Curr. Rheumatol. Rep., 11, 70, 10.1007/s11926-009-0010-8 Miyakis, 2006, International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS), J. Thromb. Haemost., 4, 295, 10.1111/j.1538-7836.2006.01753.x Hughes, 1985, The anticardiolipin syndrome, Clin. Exp. Rheumatol., 3, 285 Mackworth-Young, 1989, Primary antiphospholipid syndrome: features of patients with raised anticardiolipin antibodies and no other disorder, Ann. Rheum. Dis., 48, 362, 10.1136/ard.48.5.362 Asherson, 1988, A “primary” antiphospholipid syndrome?, J. Rheumatol., 15, 1742 Mok, 2005, Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups, Arthritis Rheum., 52, 2774, 10.1002/art.21224 Tektonidou, 2009, Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies, Arthritis Rheum., 61, 29, 10.1002/art.24232 Ruiz-Irastorza, 2004, High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus, Arch. Intern Med., 164, 77, 10.1001/archinte.164.1.77 Opatrny, 2006, Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune disease: a metaanalysis, J. Rheumatol., 33, 2214 Gomez-Puerta, 2005, Long-term follow-up in 128 patients with primary antiphospholipid syndrome: do they develop lupus?, Med. Baltim., 84, 225, 10.1097/01.md.0000172074.53583.ea Mujic, 1995, Primary antiphospholipid syndrome evolving into systemic lupus erythematosus, J. Rheumatol., 22, 1589 Cervera, 2015, Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients, Ann. Rheum. Dis., 74, 1011, 10.1136/annrheumdis-2013-204838 Borchers, 2010, The geoepidemiology of systemic lupus erythematosus, Autoimmun. Rev., 9, A277, 10.1016/j.autrev.2009.12.008 Reshetniak, 2003, Survival and prognostic factors of death risk in antiphospholipid syndrome: results of 8-year follow-up, Ter. Arkh, 75, 46 Cervera, 2003, Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients, Med. Baltim., 82, 299, 10.1097/01.md.0000091181.93122.55 Wilson, 1999, International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop, Arthritis Rheum., 42, 1309, 10.1002/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F Bobba, 2007, A review of the sapporo and revised Sapporo criteria for the classification of antiphospholipid syndrome. Where do the revised sapporo criteria add value?, J. Rheumatol., 34, 1522 Hochberg, 1997, Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus, Arthritis Rheum., 40, 1725, 10.1002/art.1780400928 Piette, 1993, Exclusion criteria for primary antiphospholipid syndrome, J. Rheumatol., 20, 1802 Meroni, 2004, Inflammatory response and the endothelium, Thromb. Res., 114, 329, 10.1016/j.thromres.2004.06.045 Ruiz-Irastorza, 2011, Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies, Lupus, 20, 206, 10.1177/0961203310395803 Barbhaiya, 2011, Primary thrombosis prophylaxis in antiphospholipid antibody-positive patients: where do we stand?, Curr. Rheumatol. Rep., 13, 59, 10.1007/s11926-010-0149-3 Forastiero, 2005, A prospective study of antibodies to beta2-glycoprotein I and prothrombin, and risk of thrombosis, J. Thromb. Haemost., 3, 1231, 10.1111/j.1538-7836.2005.01295.x Galli, 2007, Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study, Blood, 110, 1178, 10.1182/blood-2007-01-066043 Urbanus, 2009, Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study, Lancet Neurol., 8, 998, 10.1016/S1474-4422(09)70239-X Pengo, 2010, Clinical course of high-risk patients diagnosed with antiphospholipid syndrome, J. Thromb. Haemost., 8, 237, 10.1111/j.1538-7836.2009.03674.x Galli, 2003, Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome, Blood, 102, 2717, 10.1182/blood-2002-11-3334 Galli, 2003, Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature, Blood, 101, 1827, 10.1182/blood-2002-02-0441 Martinez-Berriotxoa, 2007, Transiently positive anticardiolipin antibodies and risk of thrombosis in patients with systemic lupus erythematosus, Lupus, 16, 810, 10.1177/0961203307083316 Erkan, 2011, Antiphospholipid syndrome clinical research task force report, Lupus, 20, 219, 10.1177/0961203310395053 Nalli, 2014, Management of recurrent thrombosis in antiphospholipid syndrome, Curr. Rheumatol. Rep., 16, 405, 10.1007/s11926-013-0405-4 Urowitz, 2016, Modified framingham risk factor score for systemic lupus erythematosus, J. Rheumatol., 43, 875, 10.3899/jrheum.150983 Otomo, 2012, Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events, Arthritis Rheum., 64, 504, 10.1002/art.33340 Sciascia, 2013, GAPSS: the global anti-phospholipid syndrome score, Rheumatol. Oxf., 52, 1397, 10.1093/rheumatology/kes388 Barbar, 2010, A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score, J. Thromb. Haemost., 8, 2450, 10.1111/j.1538-7836.2010.04044.x Bruce, 2005, 'Not only...but also': factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus, Rheumatol. Oxf., 44, 1492, 10.1093/rheumatology/kei142 Ceccarelli, 2012, Thromboprophylaxis in carriers of antiphospholipid antibodies (APL) without previous thrombosis: “Pros” and “Cons”, Autoimmun. Rev., 11, 568, 10.1016/j.autrev.2011.10.014 Wahl, 2000, Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies: do the benefits outweigh the risks? A decision analysis, Arch. Intern Med., 160, 2042, 10.1001/archinte.160.13.2042 Arnaud, 2014, Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis, Autoimmun. Rev., 13, 281, 10.1016/j.autrev.2013.10.014 Leung, 2002, Mortality and malignancy in the multi-ethnic Birmingham lupus cohort aspirin use is beneficial and non-Caucasian origin is not associated with poor outcome, Rheumatology, 41, S17 Cuadrado, 2014, Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS), Rheumatol. Oxf., 53, 275, 10.1093/rheumatology/ket313 Ruiz-Irastorza, 2010, Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review, Ann. Rheum. Dis., 69, 20, 10.1136/ard.2008.101766 Jung, 2010, The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus, Arthritis Rheum., 62, 863, 10.1002/art.27289 Mok, 2005, Antiphospholipid antibody profiles and their clinical associations in Chinese patients with systemic lupus erythematosus, J. Rheumatol., 32, 622 Belizna, 2015, Hydroxychloroquine as an anti-thrombotic in antiphospholipid syndrome, Autoimmun. Rev., 14, 358, 10.1016/j.autrev.2014.12.006 Borba, 2001, Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy, J. Rheumatol., 28, 780 Cairoli, 2012, Hydroxychloroquine reduces low-density lipoprotein cholesterol levels in systemic lupus erythematosus: a longitudinal evaluation of the lipid-lowering effect, Lupus, 21, 1178, 10.1177/0961203312450084 Tam, 2000, Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus, J. Rheumatol., 27, 2142 Espinola, 2002, Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies, Thromb. Haemost., 87, 518, 10.1055/s-0037-1613033 Durcan, 2016, Longitudinal evaluation of lipoprotein variables in systemic lupus erythematosus reveals adverse changes with disease activity and prednisone and more favorable profiles with hydroxychloroquine therapy, J. Rheumatol., 43, 745, 10.3899/jrheum.150437 Broder, 2013, Hydroxychloroquine use is associated with lower odds of persistently positive antiphospholipid antibodies and/or lupus anticoagulant in systemic lupus erythematosus, J. Rheumatol., 40, 30, 10.3899/jrheum.120157 Kaiser, 2009, Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort, Ann. Rheum. Dis., 68, 238, 10.1136/ard.2008.093013 Ruffatti, 2011, Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study, Ann. Rheum. Dis., 70, 1083, 10.1136/ard.2010.142042 Doria, 2003, Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus, Ann. Rheum. Dis., 62, 1071, 10.1136/ard.62.11.1071 Haque, 2010, Risk factors for clinical coronary heart disease in systemic lupus erythematosus: the lupus and atherosclerosis evaluation of risk (LASER) study, J. Rheumatol., 37, 322, 10.3899/jrheum.090306 Manzi, 1999, Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus, Arthritis Rheum., 42, 51, 10.1002/1529-0131(199901)42:1<51::AID-ANR7>3.0.CO;2-D Bruce, 1999, Natural history of hypercholesterolemia in systemic lupus erythematosus, J. Rheumatol., 26, 2137 Leong, 1994, Lipid profiles in patients with systemic lupus erythematosus, J. Rheumatol., 21, 1264 Petri, 1992, Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: prevalence, recognition by patients, and preventive practices, Med. Baltim., 71, 291, 10.1097/00005792-199209000-00004 Zen, 2011, The kaleidoscope of glucocorticoid effects on immune system, Autoimmun. Rev., 10, 305, 10.1016/j.autrev.2010.11.009 van Vollenhoven, 2016, Cumulative corticosteroids over 52 weeks in patients with systemic lupus erythematosus: pooled analyses from the phase III belimumab trials, Arthritis Rheumatol., 68, 2184, 10.1002/art.39682 Artenjak, 2012, Antiphospholipid antibodies as non-traditional risk factors in atherosclerosis based cardiovascular diseases without overt autoimmunity. A critical updated review, Autoimmun. Rev., 11, 873, 10.1016/j.autrev.2012.03.002 Lateef, 2013, Managing lupus patients during pregnancy, Best. Pract. Res. Clin. Rheumatol., 27, 435, 10.1016/j.berh.2013.07.005 Del Ross, 2013, Treatment of 139 pregnancies in antiphospholipid-positive women not fulfilling criteria for antiphospholipid syndrome: a retrospective study, J. Rheumatol., 40, 425, 10.3899/jrheum.120576 Fishman, 1993, Prevention of fetal loss in experimental antiphospholipid syndrome by in vivo administration of recombinant interleukin-3, J. Clin. Invest, 91, 1834, 10.1172/JCI116396 Roberge, 2012, Early administration of low-dose aspirin for the prevention of severe and mild preeclampsia: a systematic review and meta-analysis, Am. J. Perinatol., 29, 551 Roberge, 2012, Early administration of low-dose aspirin for the prevention of preterm and term preeclampsia: a systematic review and meta-analysis, Fetal Diagn. Ther., 31, 141, 10.1159/000336662 Andreoli, 2016, EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome, Ann. Rheum. Dis., 10.1136/annrheumdis-2016-209770 Empson, 2005, Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant, Cochrane Database Syst. Rev., 10.1002/14651858.CD002859.pub2 Erkan, 2008, Management of the controversial aspects of the antiphospholipid syndrome pregnancies: a guide for clinicians and researchers, Rheumatol. Oxf., 47, iii23 Mak, 2010, Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression, Rheumatol. Oxf., 49, 281, 10.1093/rheumatology/kep373 Cervera, 2009, Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients, Ann. Rheum. Dis., 68, 1428, 10.1136/ard.2008.093179 García-Carrasco, 2007, Antiphospholipid syndrome in Latin American patients: clinical and immunologic characteristics and comparison with European patients, Lupus, 16, 366, 10.1177/0961203307077108 Neville, 2009, Antiphospholipid antibodies predict imminent vascular events independently from other risk factors in a prospective cohort, Thromb. Haemost., 101, 100, 10.1160/TH08-06-0384 Kearon, 2012, Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines, Chest, 141, e419S, 10.1378/chest.11-2301 Les, 2012, Intensity and duration of anticoagulation therapy in antiphospholipid syndrome, Semin. Thromb. Hemost., 38, 339, 10.1055/s-0032-1304720 Meroni, 2012, Obstetric and vascular APS: same autoantibodies but different diseases?, Lupus, 21, 708, 10.1177/0961203312438116 Pengo, 2012, High intensity anticoagulation in the prevention of the recurrence of arterial thrombosis in antiphospholipid syndrome: 'PROS' and 'CONS', Autoimmun. Rev., 11, 577, 10.1016/j.autrev.2011.10.016 Okuma, 2009, Comparison between single antiplatelet therapy and combination of antiplatelet and anticoagulation therapy for secondary prevention in ischemic stroke patients with antiphospholipid syndrome, Int. J. Med. Sci., 7, 15 Giannubilo, 2012, Anticoagulant therapy during pregnancy for maternal and fetal acquired and inherited thrombophilia, Curr. Med. Chem., 19, 4562, 10.2174/092986712803306466 Sciascia, 2016, Non-vitamin K antagonist oral anticoagulants and antiphospholipid syndrome, Rheumatol. Oxf., 55, 1726, 10.1093/rheumatology/kev445 Noel, 2015, Safety and efficacy of oral direct inhibitors of thrombin and factor Xa in antiphospholipid syndrome, Autoimmun. Rev., 14, 680, 10.1016/j.autrev.2015.03.007 Chighizola, 2014, New oral anticoagulants in thrombotic antiphospholipid syndrome, Lupus, 23, 1279, 10.1177/0961203314540968 Cohen, 2015, Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE, Lupus, 24, 1087, 10.1177/0961203315581207 Pengo, 2016, Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial, Lupus, 25, 301, 10.1177/0961203315611495 Wu, 2014, The medical management of antiphospholipid syndrome in pregnancy: a meta-analysis, Obstet. Gynecol., 123, 178s, 10.1097/01.AOG.0000447195.12926.b9 Pettila, 2002, Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin, Thromb. Haemost., 87, 182, 10.1055/s-0037-1612970 Reggia, 2014, Current treatment strategies for management of antiphospholipid syndrome, Expert Opin. Orphan Drugs, 2 Ginsberg, 2001, Use of antithrombotic agents during pregnancy, Chest, 119, 122S, 10.1378/chest.119.1_suppl.122S Ostensen, 2006, Anti-inflammatory and immunosuppressive drugs and reproduction, Arthritis Res. Ther., 8, 209, 10.1186/ar1957 Bramham, 2011, First-trimester low-dose prednisolone in refractory antiphospholipid antibody-related pregnancy loss, Blood, 117, 6948, 10.1182/blood-2011-02-339234 Vaquero, 2001, Pregnancy outcome in recurrent spontaneous abortion associated with antiphospholipid antibodies: a comparative study of intravenous immunoglobulin versus prednisone plus low-dose aspirin, Am. J. Reprod. Immunol., 45, 174, 10.1111/j.8755-8920.2001.450309.x Ruffatti, 2014, Treatment strategies and pregnancy outcomes in antiphospholipid syndrome patients with thrombosis and triple antiphospholipid positivity. A European multicentre retrospective study, Thromb. Haemost., 112, 727, 10.1160/TH14-03-0191 Eriksson, 2012, Physical activity in patients with systemic lupus erythematosus and matched controls, Scand. J. Rheumatol., 41, 290, 10.3109/03009742.2011.624117 Remans, 2004, Nutrient supplementation with polyunsaturated fatty acids and micronutrients in rheumatoid arthritis: clinical and biochemical effects, Eur. J. Clin. Nutr., 58, 839, 10.1038/sj.ejcn.1601883 Yokoyama, 2007, Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis, Lancet, 369, 1090, 10.1016/S0140-6736(07)60527-3 Wright, 2008, A randomised interventional trial of omega-3-polyunsaturated fatty acids on endothelial function and disease activity in systemic lupus erythematosus, Ann. Rheum. Dis., 67, 841, 10.1136/ard.2007.077156 Bello, 2013, Omega-3 in SLE: a double-blind, placebo-controlled randomized clinical trial of endothelial dysfunction and disease activity in systemic lupus erythematosus, Rheumatol. Int., 33, 2789, 10.1007/s00296-013-2811-3 Agmon-Levin, 2011, Vitamin D: an instrumental factor in the anti-phospholipid syndrome by inhibition of tissue factor expression, Ann. Rheum. Dis., 70, 145, 10.1136/ard.2010.134817 Piantoni, 2012, Low levels of vitamin D are common in primary antiphospholipid syndrome with thrombotic disease, Reumatismo, 64, 307, 10.4081/reumatismo.2012.307 Sahebari, 2014, Correlation between serum 25(OH)D values and lupus disease activity: an original article and a systematic review with meta-analysis focusing on serum VitD confounders, Lupus, 23, 1164, 10.1177/0961203314540966 Reynolds, 2012, 25-Hydroxyvitamin D deficiency is associated with increased aortic stiffness in patients with systemic lupus erythematosus, Rheumatol. Oxf., 51, 544, 10.1093/rheumatology/ker352 Poole, 2006, Reduced vitamin D in acute stroke, Stroke, 37, 243, 10.1161/01.STR.0000195184.24297.c1 Ravenell, 2012, Premature atherosclerosis is associated with hypovitaminosis D and angiotensin-converting enzyme inhibitor non-use in lupus patients, Am. J. Med. Sci., 344, 268, 10.1097/MAJ.0b013e31823fa7d9 Ridker, 2013, Statins: new American guidelines for prevention of cardiovascular disease, Lancet, 382, 1762, 10.1016/S0140-6736(13)62388-0 Ridker, 2009, Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial, Lancet, 373, 1175, 10.1016/S0140-6736(09)60447-5 Kotyla, 2006, Tumor necrosis factor-alpha as a potential target in the treatment of systemic lupus erythematosus: a role for the HMG-CoA reductase inhibitor simvastatin, J. Rheumatol., 33, 2361 Riboldi, 2005, Statins and autoimmune diseases, Lupus, 14, 765, 10.1191/0961203305lu2217oa Tang, 2011, Atorvastatin upregulates regulatory T cells and reduces clinical disease activity in patients with rheumatoid arthritis, J. Lipid Res., 52, 1023, 10.1194/jlr.M010876 Wang, 2015, Changes of naturally occurring CD4(+)CD25(+) FOXP3(+) regulatory T cells in patients with acute coronary syndrome and the beneficial effects of atorvastatin treatment, Int. heart J., 56, 163, 10.1536/ihj.14-245 Ferreira, 2007, Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial, Rheumatol. Oxf., 46, 1560, 10.1093/rheumatology/kem186 Plazak, 2011, Influence of atorvastatin on coronary calcifications and myocardial perfusion defects in systemic lupus erythematosus patients: a prospective, randomized, double-masked, placebo-controlled study, Arthritis Res. Ther., 13, R117, 10.1186/ar3402 Sahebkar, 2016, Statin impact on disease activity and C-reactive protein concentrations in systemic lupus erythematosus patients: a systematic review and meta-analysis of controlled trials, Autoimmun. Rev., 15, 344, 10.1016/j.autrev.2015.12.007 Mok, 2011, Effects of rosuvastatin on vascular biomarkers and carotid atherosclerosis in lupus: a randomized, double-blind, placebo-controlled trial, Arthritis Care Res. Hob., 63, 875, 10.1002/acr.20440 Jajoria, 2009, Statins for the treatment of antiphospholipid syndrome?, Ann. N. Y. Acad. Sci., 1173, 736, 10.1111/j.1749-6632.2009.04815.x Soubrier, 2013, Do all lupus patients need statins?, Jt. Bone Spine, 80, 244, 10.1016/j.jbspin.2012.08.014 Petri, 2011, Lupus atherosclerosis prevention study (LAPS), Ann. Rheum. Dis., 70, 760, 10.1136/ard.2010.136762 Berman, 2013, Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab, Autoimmun. Rev., 12, 1085, 10.1016/j.autrev.2013.05.004 Sciascia, 2012, Prevention of thrombosis relapse in antiphospholipid syndrome patients refractory to conventional therapy using intravenous immunoglobulin, Clin. Exp. Rheumatol., 30, 409 Erkan, 2013, A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome, Arthritis Rheum., 65, 464, 10.1002/art.37759 Bakhtar, 2014, A case of thrombotic microangiopathy associated with antiphospholipid antibody syndrome successfully treated with eculizumab, Transplantation, 98, e17, 10.1097/TP.0000000000000267 Lonze, 2014, Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation, Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transpl. Surg., 14, 459, 10.1111/ajt.12540 Bucciarelli, 2006, Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients, Arthritis Rheum., 54, 2568, 10.1002/art.22018 Shapira, 2012, Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab, Arthritis Rheum., 64, 2719, 10.1002/art.34440 Canaud, 2014, Inhibition of the mTORC pathway in the antiphospholipid syndrome, N. Engl. J. Med., 371, 303, 10.1056/NEJMoa1312890 Doria, 2006, Long-term prognosis and causes of death in systemic lupus erythematosus, Am. J. Med., 119, 700, 10.1016/j.amjmed.2005.11.034 Bertsias, 2010, EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs, Ann. Rheum. Dis., 69, 2074, 10.1136/ard.2010.130476 Moroni, 2004, Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis, Am. J. Kidney Dis., 43, 28, 10.1053/j.ajkd.2003.09.011 Taraborelli, 2016, The contribution of antiphospholipid antibodies to organ damage in systemic lupus erythematosus, Lupus, 25, 1365, 10.1177/0961203316637431